TITLE

The insulin pump looks promising for noninsulin-dependent diabetics

PUB. DATE
January 1997
SOURCE
Modern Medicine;Jan97, Vol. 65 Issue 1, p21
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on a study led by Christopher D. Saudek showing the effectiveness of implantable insulin pumps in treating noninsulin-dependent diabetes. Advantages over injections; Glycemic control; Weight gain; Quality of life; Cost; Side effects.
ACCESSION #
9702034175

 

Related Articles

  • A Prospective Trial of U500 Insulin Delivered by Omnipod in Patients With Type 2 Diabetes Mellitus and Severe Insulin Resistance. Wendy Lane; Stephen Weinrib; Jonathan Rappaport; Therese Przestrzelski // Endocrine Practice;Sep2010, Vol. 16 Issue 5, p778 

    Objective: To test the effectiveness and safety of U500 regular insulin delivered by continuous subcutaneous insulin infusion (CSII) via the Omnipod insulin delivery system in patients with uncontrolled type 2 diabetes mellitus and severe insulin resistance.Methods: In this prospective, 1-year,...

  • A Prospective Trial of U500 Insulin Delivered by Omnipod in Patients With Type 2 Diabetes Mellitus and Severe Insulin Resistance. Wendy Lane; Stephen Weinrib; Jonathan Rappaport; Therese Przestrzelski // Endocrine Practice;Sep2010, Vol. 16 Issue 5, p778 

    Objective: To test the effectiveness and safety of U500 regular insulin delivered by continuous subcutaneous insulin infusion (CSII) via the Omnipod insulin delivery system in patients with uncontrolled type 2 diabetes mellitus and severe insulin resistance.Methods: In this prospective, 1-year,...

  • Pharmacokinetic and Pharmacodynamic Effects of a SC Infusion of Insulin Lispro by a Disposable Basal Insulin Pump in Healthy Volunteers. Rave, Klaus; Heinemann, Lutz; Gravesen, Peter // Diabetes;Jun2007 Supplement 1, Vol. 56, pA120 

    Basal infusion of insulin with a constant rate over a period of at least 3 days is an attractive option for patients with type 2 diabetes. In comparison to SC injection of long-acting insulin analogues this should led to a more constant metabolic effect. A novel disposable Microfluidic Elastomer...

  • Insulin Aspart (rDNA Origin) Injection.  // AHFS Consumer Medication Information;Oct2019, p1 

    Insulin aspart is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and therefore...

  • Take Care of Your Diabetes Each Day: Take Your Medicines as Prescribed.  // Guía para Personas con Diabetes Tipo 1 y Tipo 2;2013, p16 

    A chapter of the book "Your Guide to Diabetes: Type 1 and 2" is presented which provides information on taking medicines as prescribed for daily management of diabetes. Topics discussed include the use of medicines by people with type 2 diabetes to help stabilize their blood glucose levels,...

  • QOL improved in people using an insulin bolus-patch.  // Diabetes Digest;2012, Vol. 11 Issue 1, p39 

    The article presents a study on the effectiveness, device satisfaction and quality of life (QOL) in diabetic people using a novel insulin bolus-patch, in which study reveals that bolus-patch insulin expressed good quality tolerability, improve QOL and significant device satisfaction.

  • Limitations of HbA[sub1c] in diabetes control.  // Pulse;3/24/2003, Vol. 63 Issue 12, p88 

    Discusses the limitations of the HbA[sub 1c] in aiding the treatment of type 2 diabetes. Method of monitoring the effectiveness of therapy in diabetes; Clinical advantages of measuring fructosamine level.

  • New diabetes treatments may be on horizon.  // Diabetes in the News;Nov/Dec94, Vol. 13 Issue 6, p3 

    Reports on studies regarding new therapies for type II diabetes. Food and Drug Administration's (FDA) pending approval of an oral agent called metformin; Studies on thiazoles and vanadates; Mechanism of action of tolrestat; Use of combination drug approach in diabetes-related impotence; Use of...

  • Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes.  // Formulary;Feb2010, Vol. 45 Issue 2, p34 

    An abstract of the article "Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes," by Ashley Krause and Jennifer Kirwin is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics